(TRNS) Transcat - Overview
Stock: Calibration, Instrument, Services, Distribution
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 53.4% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.11 |
| Alpha | -14.27 |
| Character TTM | |
|---|---|
| Beta | 0.604 |
| Beta Downside | 0.571 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.86% |
| CAGR/Max DD | -0.06 |
Description: TRNS Transcat January 25, 2026
Transcat, Inc. (NASDAQ: TRNS) delivers calibration and laboratory-instrument services across the U.S., Canada, and select international markets, organized into a Service segment and a Distribution segment.
The Service segment generates revenue by offering calibration, repair, inspection, analytical qualification, preventative maintenance, and consulting. It also licenses CalTrak, a proprietary workflow and asset-management platform, and the Compliance, Control, and Cost portal that stores customers’ calibration records securely online. In FY 2024 the Service segment contributed roughly 62 % of total revenue, posting a 7 % year-over-year increase driven by heightened demand for FDA-compliant calibration in the life-science sector.
The Distribution segment sells and rents test, measurement, and control instruments, and adds value through equipment certification, rental programs, used-equipment sales, and kitting services. This segment accounted for about 38 % of FY 2024 revenue and saw a 4 % YoY rise, reflecting continued capital-expenditure growth in aerospace, defense, and energy firms that are modernizing their measurement infrastructure.
Key economic and sector drivers include: (1) a projected 5-6 % CAGR in global life-science equipment spend through 2028, (2) tighter FDA and international regulatory standards that increase calibration frequency, and (3) a rebound in industrial manufacturing CAPEX after the 2023-24 supply-chain disruptions, which lifts demand for both new and serviced instrumentation.
Assuming the FY 2025 guidance holds, TRNS’s operating margin is expected to stay in the low-teens, but a material shift in the regulatory environment or a slowdown in industrial CAPEX could materially affect earnings; any such change would warrant a revision of the outlook.
For a deeper, data-driven valuation framework, you might find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 9.10m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.23 > 1.0 |
| NWC/Revenue: 13.79% < 20% (prev 16.42%; Δ -2.63% < -1%) |
| CFO/TA 0.08 > 3% & CFO 39.3m > Net Income 9.10m |
| Net Debt (130.5m) to EBITDA (41.7m): 3.13 < 3 |
| Current Ratio: 2.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (9.33m) vs 12m ago 0.51% < -2% |
| Gross Margin: 32.41% > 18% (prev 0.33%; Δ 3208 % > 0.5%) |
| Asset Turnover: 74.61% > 50% (prev 70.79%; Δ 3.81% > 0%) |
| Interest Coverage Ratio: 4.53 > 6 (EBITDA TTM 41.7m / Interest Expense TTM 3.71m) |
Altman Z'' 2.13
| A: 0.09 (Total Current Assets 80.8m - Total Current Liabilities 36.6m) / Total Assets 472.9m |
| B: 0.20 (Retained Earnings 95.8m / Total Assets 472.9m) |
| C: 0.04 (EBIT TTM 16.8m / Avg Total Assets 429.4m) |
| D: 0.57 (Book Value of Equity 100.0m / Total Liabilities 176.1m) |
| Altman-Z'' Score: 2.13 = BBB |
Beneish M -2.89
| DSRI: 0.97 (Receivables 59.8m/52.4m, Revenue 320.4m/273.3m) |
| GMI: 1.01 (GM 32.41% / 32.61%) |
| AQI: 1.16 (AQ_t 0.71 / AQ_t-1 0.61) |
| SGI: 1.17 (Revenue 320.4m / 273.3m) |
| TATA: -0.06 (NI 9.10m - CFO 39.3m) / TA 472.9m) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of TRNS shares?
Over the past week, the price has changed by +26.56%, over one month by +25.77%, over three months by +31.56% and over the past year by -1.90%.
Is TRNS a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TRNS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 101.3 | 32.8% |
| Analysts Target Price | 101.3 | 32.8% |
| ValueRay Target Price | 75.2 | -1.5% |
TRNS Fundamental Data Overview February 07, 2026
P/E Forward = 31.9489
P/S = 2.0551
P/B = 2.2308
Revenue TTM = 320.4m USD
EBIT TTM = 16.8m USD
EBITDA TTM = 41.7m USD
Long Term Debt = 30.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 4.88m USD (from shortTermDebt, last quarter)
Debt = 134.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 130.5m USD (from netDebt column, last quarter)
Enterprise Value = 787.5m USD (657.0m + Debt 134.0m - CCE 3.47m)
Interest Coverage Ratio = 4.53 (Ebit TTM 16.8m / Interest Expense TTM 3.71m)
EV/FCF = 31.66x (Enterprise Value 787.5m / FCF TTM 24.9m)
FCF Yield = 3.16% (FCF TTM 24.9m / Enterprise Value 787.5m)
FCF Margin = 7.76% (FCF TTM 24.9m / Revenue TTM 320.4m)
Net Margin = 2.84% (Net Income TTM 9.10m / Revenue TTM 320.4m)
Gross Margin = 32.41% ((Revenue TTM 320.4m - Cost of Revenue TTM 216.6m) / Revenue TTM)
Gross Margin QoQ = 30.11% (prev 32.53%)
Tobins Q-Ratio = 1.67 (Enterprise Value 787.5m / Total Assets 472.9m)
Interest Expense / Debt = 1.12% (Interest Expense 1.50m / Debt 134.0m)
Taxrate = 20.80% (3.81m / 18.3m)
NOPAT = 13.3m (EBIT 16.8m * (1 - 20.80%))
Current Ratio = 2.21 (Total Current Assets 80.8m / Total Current Liabilities 36.6m)
Debt / Equity = 0.45 (Debt 134.0m / totalStockholderEquity, last quarter 296.8m)
Debt / EBITDA = 3.13 (Net Debt 130.5m / EBITDA 41.7m)
Debt / FCF = 5.25 (Net Debt 130.5m / FCF TTM 24.9m)
Total Stockholder Equity = 292.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.12% (Net Income 9.10m / Total Assets 472.9m)
RoE = 3.11% (Net Income TTM 9.10m / Total Stockholder Equity 292.9m)
RoCE = 5.19% (EBIT 16.8m / Capital Employed (Equity 292.9m + L.T.Debt 30.9m))
RoIC = 3.79% (NOPAT 13.3m / Invested Capital 351.3m)
WACC = 6.91% (E(657.0m)/V(791.0m) * Re(8.14%) + D(134.0m)/V(791.0m) * Rd(1.12%) * (1-Tc(0.21)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.24%
[DCF Debug] Terminal Value 84.89% ; FCFF base≈22.7m ; Y1≈28.0m ; Y5≈47.7m
Fair Price DCF = 96.49 (EV 1.03b - Net Debt 130.5m = Equity 900.4m / Shares 9.33m; r=6.91% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 23.79 | EPS CAGR: -10.85% | SUE: -1.39 | # QB: 0
Revenue Correlation: 96.90 | Revenue CAGR: 11.43% | SUE: 1.15 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.51 | Chg30d=-0.020 | Revisions Net=-2 | Analysts=2
EPS next Year (2027-03-31): EPS=2.15 | Chg30d=-0.048 | Revisions Net=-2 | Growth EPS=+16.7% | Growth Revenue=+7.4%